Search
Influenza A virus A/Idaho/07/2018 (H1N1) antigen (MDCK cell derived, propiolactone inactivated
go.drugbank.com/drugs/DB15505ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza A virus A/Switzerland/3330/2017 (H1N1) live (attenuated) antigen
go.drugbank.com/drugs/DB15513ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza A virus A/Brisbane/02/2018 IVR-190 (H1N1) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB15515ApprovedVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza A virus A/Kansas/14/2017 X-327 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB15516ApprovedVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza A virus A/Kansas/14/2017 X-327 (H3N2) antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB15520ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza B virus B/Iowa/06/2017 hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB15563ApprovedVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza A virus A/Guangdong-Maonan/SWL1536/2019 CNIC-1909 (H1N1) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB15703ApprovedInvestigationalVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza A virus A/Delaware/39/2019 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB15708ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza A virus A/Hong Kong/2671/2019 IVR-208 (H3N2) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB15712ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza A virus A/Guangdong-Maonan/SWL1536/2019 CNIC-1909 (H1N1) antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB15714ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.